Microbot's LIBERTY robot sales slump 70% quarter on quarter, with negative gross margin
Microbot Medical reported third-quarter revenue of $72,000 and a gross loss, but holds about $62m in cash and has signed Medtechnica as its Israeli distributor.
Microbot Medical's third-quarter sales of its LIBERTY endovascular robotic system came to $72,000, roughly 70% below the $241,000 booked in the second quarter, according to the 10-Q for the period ended 30 September 2026. The company announced the filing on 16 November.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Microbot Medical Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.